High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 692-694

  Silveira, Marina G ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EDITORIAL; HUMAN; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

CHOLANGITIS, SCLEROSING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; URSODEOXYCHOLIC ACID;

EID: 41049117931     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.02.002     Document Type: Editorial

References (24)

1. Cullen S.N., Rust C., Fleming K., Edwards C., Beuers U., and Chapman R.W. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 48 (2008) 792-800
2. Bjornsson E., and Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 102 (2007) 1677-1682
3. Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16 (1992) 707-714
4. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 (1997) 691-695
5. O'Brien C.B., Senior J.R., Arora-Mirchandani R., Batta A.K., and Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14 (1991) 838-847
6. Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W.J., and Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20 (1994) 57-64
7. De Maria N., Colantoni A., Rosenbloom E., and Van Thiel D.H. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 43 (1996) 1472-1479
8. van Hoogstraten H.J., Wolfhagen F.H., van de Meeberg P.C., Kuiper H., Nix G.A., Becx M.C., et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 29 (1998) 417-423
9. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., and Chapman R.W. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 (2001) 900-907
10. Harnois D.M., Angulo P., Jorgensen R.A., Larusso N.F., and Lindor K.D. High dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 (2001) 1558-1562
11. Okolicsanyi L., Groppo M., Floreani A., Morselli-Labate A.M., Rusticali A.G., Battocchia A., et al. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis 35 (2003) 325-331
12. Angulo P., Dickson E.R., Therneau T.M., Jorgensen R.A., Smith C., DeSotel C.K., et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 30 (1999) 830-835
13. Nakagawa M., Colombo C., and Setchell K.D. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 12 (1990) 322-334
14. Colombo C., Setchell K.D., Podda M., Crosignani A., Roda A., Curcio L., et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 117 (1990) 482-489
15. Colombo C., Crosignani A., Assaisso M., Battezzati P.M., Podda M., Giunta A., et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 16 (1992) 924-930
16. Olsson R., Boberg K.M., de Muckadell O.S., Lindgren S., Hultcrantz R., Folvik G., et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129 (2005) 1464-1472
17. Rost D., Rudolph G., Kloeters-Plachky P., and Stiehl A. Effect of high dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40 (2004) 693-698
18. Rockey D.C., and Bissell D.M. Noninvasive measures of liver fibrosis. Hepatology 43 (2006) S113-S120
19. Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75 (2000) 688-694
20. Dickson E.R., Murtaugh P.A., Wiesner R.H., Grambsch P.M., Fleming T.R., Ludwig J., et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103 (1992) 1893-1901
21. Shetty K., Rybicki L., and Carey W.D. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 25 (1997) 1049-1053
22. Kim W.R., Poterucha J.J., Wiesner R.H., LaRusso N.F., Lindor K.D., Petz J., et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29 (1999) 1643-1648
23. Talwalkar J.A., and Lindor K.D. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15 (2001) 563-575
24. Boberg K.M., Rocca G., Egeland T., Bergquist A., Broome U., Caballeria L., et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 35 (2002) 652-657